RESECTABLE HEPATOCELLULAR CARCINOMA
Clinical trials for RESECTABLE HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for RESECTABLE HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple immunotherapy cocktail aims to boost surgery success in liver cancer
Disease control Not yet recruitingThis phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study…
Matched conditions: RESECTABLE HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug combo aims to shrink liver tumors before surgery
Disease control Not yet recruitingThis study tests whether giving two drugs (ateganosine and cadonilimab) before surgery can safely shrink liver tumors in people with resectable hepatocellular carcinoma. About 60 participants will receive either one or both drugs before their operation. The main goal is to see if…
Matched conditions: RESECTABLE HEPATOCELLULAR CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC